0001209191-19-012998.txt : 20190225
0001209191-19-012998.hdr.sgml : 20190225
20190225164026
ACCESSION NUMBER: 0001209191-19-012998
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190221
FILED AS OF DATE: 20190225
DATE AS OF CHANGE: 20190225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GREGORY JULIA P
CENTRAL INDEX KEY: 0001226675
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 19630081
MAIL ADDRESS:
STREET 1: 8800 TECHNOLOGY FOREST PLACE
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-21
0
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001226675
GREGORY JULIA P
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN
CT
06510
1
0
0
0
Common Shares
2019-02-21
4
M
0
12000
23.63
A
12000
D
Common Shares
2019-02-21
4
S
0
12000
43.56
D
0
D
Stock Option (Right to Buy)
23.63
2019-02-21
4
M
0
12000
0.00
D
2027-08-01
Common Shares
12000
24000
D
This exercise and the subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 22, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 - $44.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
This option grant was made pursuant to the Issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
/s/ Darren DeStefano, Attorney-in-Fact
2019-02-25